



Date: 24 SEPTEMBER 2019

Sydney, Australia

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

DEPARTURE OF DR VAN WYK

Sydney, 24 September 2019: Noxopharm (ASX:NOX) announces today that Dr Greg Van Wyk is departing the business.

Dr Van Wyk, who has been with Noxopharm for 10 months and was initially employed as its Chief Medical Officer, has worked with Executive Chairman, Dr Graham Kelly, to build an experienced management team dedicated to bringing Veyonda[®] through clinical trials and towards marketing approval.

Dr Kelly will work with the Noxopharm executive team and the Board to ensure the ongoing development of Veyonda[®] remains on track.

Dr Kelly, said, “Noxopharm thanks Dr Van Wyk for his efforts in building the clinical team and wishes him well in his future career”.

The Board of Noxopharm has listened to recent comments by its shareholders on the need for improved investor communications in Australia and USA. The Board also recognises the need to explain the exciting news about Veyonda[®] in a more understandable way. Recent readouts from the DARRT-1 and LuPIN clinical trials point to Veyonda[®] being a potentially breakthrough adjunct therapy to radiotherapy in treating prostate cancer, with both studies showing very positive signals in clinical response rates (PSA reduction), pain reduction and disease progression. Noxopharm believes this to be exciting news which the market is entitled to fully understand.

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda[®] and is the major shareholder in Nyrada Inc.

www.noxopharm.com

**Investor & Corporate Enquiries:**

Prue Kelly

M: 0459 022 445

E: info@noxopharm.com

Company Secretary:

David Franks

T: +61 2 9299 9690

E: David.Franks@automicgroup.com.au

Media Contact:

Frank de Maria

Purposeful Communications

T: +1 347 647 0284

E: frank.demaria@purposefulcommunications.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.